Silence Therapeutics (SLN) Equity Ratio: 2023-2025
Historic Equity Ratio for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to 0.50.
- Silence Therapeutics' Equity Ratio was N/A to 0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11, marking a year-over-year change of. This contributed to the annual value of 0.66 for FY2024, which is 259.22% up from last year.
- Latest data reveals that Silence Therapeutics reported Equity Ratio of 0.50 as of Q3 2025, which was down 11.46% from 0.57 recorded in Q2 2025.
- Silence Therapeutics' Equity Ratio's 5-year high stood at 0.66 during Q4 2024, with a 5-year trough of 0.18 in Q4 2023.
- Its 3-year average for Equity Ratio is 0.51, with a median of 0.57 in 2025.
- Examining YoY changes over the last 5 years, Silence Therapeutics' Equity Ratio showed a top increase of 259.22% in 2024 and a maximum decrease of 259.22% in 2024.
- MRQ analysis of 3 years shows Silence Therapeutics' Equity Ratio stood at 0.18 in 2023, then skyrocketed by 259.22% to 0.66 in 2024, then dropped by 23.71% to 0.50 in 2025.
- Its last three reported values are 0.50 in Q3 2025, 0.57 for Q2 2025, and 0.61 during Q1 2025.